about
Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemiaThe Role of IL-17 and Th17 Lymphocytes in Autoimmune DiseasesTargets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia.Laccase purified from Cerrena unicolor exerts antitumor activity against leukemic cells.Accumulation of CD5+CD19+ B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils.Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.Gene expression profiling in MDS and AML: potential and future avenues.Tyrosine kinase inhibitors in hematological malignancies.Antigen stimulation in the development of chronic lymphocytic leukemia.Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.PD1/PD1L pathway, HLA-G and T regulatory cells as new markers of immunosuppression in cancers.Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients.Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteinsCD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians.Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients.HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML.Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia.Optogenetics in cancer drug discovery.Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis.Specific cytotoxic T-cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells.Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.Dendritic cells based immunotherapy of patient with chondrosarcoma--case report.The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia.Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells.The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia.Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance.DNA methylation signature in blood does not predict calendar age in patients with chronic lymphocytic leukemia but may alert to the presence of diseaseDecreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritisInhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cellsB-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodiesComparison of methods for determining zeta-chain associated protein - 70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL)Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemiaThe high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide
P50
Q31154933-36A1075A-8CBF-4512-9A03-738D1EC6ACF4Q33364071-9A446FEE-D504-4E13-B257-0E8F392FF32AQ34245048-EC9458AF-DC37-4593-96C6-F8944BCF78FBQ36249305-E2B4DE62-0801-4FA5-9B29-789215E8B4CEQ36637647-FBA67E8A-6C02-4C16-BC98-F2531C4DF7ACQ36640721-41D39233-3E44-42FE-BA33-3B639F6BFAB0Q37338791-B4DF4A9A-9797-4588-B98B-A5083B9DB9C0Q37802570-D867046F-D8C4-44CD-8309-2D59972B9F24Q37858877-6221DC92-150E-48C0-894C-F34B518F90C3Q37968901-8E66F3DE-DC74-4802-A562-8CBB831A887EQ38174848-1D7877F5-BF3F-4B78-9F2A-6ADAFBD15971Q39487681-AC6F92EE-91E4-4D44-AF14-F13AC171E69DQ40515635-B2D0B61A-8E71-4635-91D6-53AF55157CB2Q42272935-93A6B86E-41E5-4215-802F-7B4BCBBD1D72Q42856089-15DCA03F-B466-4898-80BF-C5030C0F1223Q44153820-D39B6C15-01DA-4062-B0C0-83BD5E43042FQ46013515-95427261-B814-4684-81EA-418E95A94D37Q46715841-63D5BB05-FC13-4916-86BB-7F061A5DEFF5Q47100838-DA11D985-DF23-4FB3-8115-224631DE7B08Q47767233-EC65A679-6B71-4D6B-BB99-DDF7A7B4FEE4Q48321488-82CF3F6D-8438-4F92-9791-6202179DCD20Q48372008-37732384-BA83-4F4B-91E8-B1F189A93E59Q49374297-743B53C4-448D-4BCB-B16E-7FAF410C4F86Q49982038-8151089A-83DB-4953-B2F9-104D68683E8CQ50122964-CE2B0222-AEFB-4A5F-8993-E54AF5413187Q50654687-EFA01C6A-F45D-493F-82E5-4131E59E20FEQ50715884-4AC443BF-FE45-43D5-8781-74E97F3468CAQ53412990-77A93FD7-A187-433E-BB7F-1F44777CBA33Q53429971-9F24B978-B912-4D54-9D61-8AD36A2D8145Q53525341-FBB170B4-D557-42FA-B514-E8E82C64D471Q54290307-33FB5215-2A4A-4011-8468-6515716621A5Q54656167-4F55165D-5BBC-423E-AB3D-0B17F4E1F009Q54731667-3B655AEE-214A-4EFE-93C0-066422417066Q57777148-D5636C4A-3CC0-42EB-84D8-BF8C8F837FD7Q58727230-3EF32BE8-DF67-4872-A4EF-741F869490F7Q59697347-4F00A658-278E-4F6A-911B-F55CDE172457Q61905852-CDE316D4-2B5D-46E1-8C57-C46A55472947Q80103632-02B40AC6-5D64-4629-B94B-D165C2F664CBQ80272180-AB37B830-9568-4C2C-AC26-E3296C55EF5FQ80685315-808F9EE1-C3D5-4FF0-B52A-5CB0F3CE79C3
P50
description
Polish hematologist and immunologist
@en
Pools onderzoeker
@nl
polski lekarz, hematolog i immunolog
@pl
name
Krzysztof Giannopoulos
@ast
Krzysztof Giannopoulos
@ca
Krzysztof Giannopoulos
@cs
Krzysztof Giannopoulos
@en
Krzysztof Giannopoulos
@es
Krzysztof Giannopoulos
@gl
Krzysztof Giannopoulos
@hr
Krzysztof Giannopoulos
@hsb
Krzysztof Giannopoulos
@it
Krzysztof Giannopoulos
@nl
type
label
Krzysztof Giannopoulos
@ast
Krzysztof Giannopoulos
@ca
Krzysztof Giannopoulos
@cs
Krzysztof Giannopoulos
@en
Krzysztof Giannopoulos
@es
Krzysztof Giannopoulos
@gl
Krzysztof Giannopoulos
@hr
Krzysztof Giannopoulos
@hsb
Krzysztof Giannopoulos
@it
Krzysztof Giannopoulos
@nl
prefLabel
Krzysztof Giannopoulos
@ast
Krzysztof Giannopoulos
@ca
Krzysztof Giannopoulos
@cs
Krzysztof Giannopoulos
@en
Krzysztof Giannopoulos
@es
Krzysztof Giannopoulos
@gl
Krzysztof Giannopoulos
@hr
Krzysztof Giannopoulos
@hsb
Krzysztof Giannopoulos
@it
Krzysztof Giannopoulos
@nl
P106
P1153
8929237100
P1412
P1559
Krzysztof Giannopoulos
@pl
P21
P27
P31
P3124
P496
0000-0003-0135-4030